BAVIS_1170X120_10-19-20

Dr. Samit Hirawat

Bristol Myers Squibb research at ASCO shows diverse approaches in treating cancer

Bristol Myers Squibb research at ASCO shows diverse approaches in treating cancer

PRINCETON, N.J. — Bristol Myers Squibb has announced the presentation of data across its portfolio, aimed at addressing solid tumor and hematologic malignancies in 28 types of cancer, at the upcoming American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program, which will take place from May 29 to May 31, 2020. Presentations will feature

FDA approves Bristol Myers Squibb’s Zeposia

FDA approves Bristol Myers Squibb’s Zeposia

PRINCETON, N.J. — Bristol-Myers Squibb Co. announced Thursday that the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.  Zeposia, an oral medication taken once daily, is the only approved